Alk Abello A/S (ALKb.CO)
23 Jul 2014
|Market Cap (Mil.):||kr.7,458.16|
|Shares Outstanding (Mil.):||9.21|
(Adds Aker Solutions, Alma Media and Norsk Hydro, updates H&M and SKF)
* Merck and partner ALK Abello expected to launch rival drug this year
COPENHAGEN - Danish pharmaceutical group Alk Abello expects to start selling its new dust mite allergy tablet in Europe and Japan around the end 2015 with the U.S. market a further year behind, its Chief Executive told Reuters on Thursday.
Earnings vs. Estimates
Analyst Research Reports
Alk Abello A/S: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.